Track the 네오팜 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 네오팜 has logged 6 public disclosures. Market capitalisation: €309.2bn. The latest transaction was filed on 8 June 2026 (Purchase). Among the most active insiders: FILLIMITED. Every trade is openly available.
Analysts rate 네오팜 Strong Buy (bullish), based on 1 analysts. Average price target: ₩24,000.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Neopharm es una empresa que opera en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se centra en el desarrollo y la comercialización de productos farmacéuticos y sanitarios.